Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion

Biotherapy. 1992;5(2):107-12. doi: 10.1007/BF02171695.


Twenty effusions in sixteen patients with malignant peritoneal and/or pleural effusions were treated with intracavitary injection of lentinan. Lentinan was injected at a dosage of 4 mg/week for 4 weeks. In total, sixteen (80%) of twenty lesions demonstrated clinical responses. Performance status was improved in seven patients. The average survival time in responders was 129 days, while, in non-responders, it was 49 days. Serious toxicities were not observed. NK activity of PBMC significantly decreased after lentinan injection. NK activity of PEC in responders was augmented significantly. Anti-Daudi and lymphokine activated killer activity were also augmented or maintained after lentinan injection.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Ascites / drug therapy*
  • Cell Survival / drug effects
  • Exudates and Transudates / cytology
  • Female
  • Humans
  • Killer Cells, Lymphokine-Activated / drug effects
  • Lentinan / administration & dosage
  • Lentinan / immunology
  • Lentinan / therapeutic use*
  • Lymphocytes / drug effects
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Neutrophils / drug effects
  • Pleural Effusion / drug therapy*


  • Lentinan